Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion
April 12th, 2020
6.9K views
Laser microdissection (LMD) is a sensitive and highly reproducible technique that can be used to uncover pathways that mediate glioma heterogeneity and invasion. Here, we describe an optimized protocol to isolate discrete areas from glioma tissue using laser LMD followed by transcriptomic analysis.
Overview
This study presents a refined protocol for laser microdissection (LMD) to isolate specific tumor regions from glioma tissue, enabling detailed transcriptomic analysis. The approach reveals pathways linked to glioma heterogeneity and invasion, contributing to a better understanding of tumor biology.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Transcriptional Analysis
Background
- Gliomas exhibit significant intratumor heterogeneity, which complicates treatment.
- Understanding the molecular pathways can provide insights into tumor behavior.
- Laser microdissection allows for spatially precise analysis of tumor regions.
- This technique aids in preserving tissue quality for subsequent analysis.
Purpose of Study
- To isolate specific areas of glioma tissue for RNA sequencing.
- To elucidate mechanisms driving glioma heterogeneity.
- To identify potential therapeutic targets for glioma treatment.
Methods Used
- The main platform utilized is laser microdissection combined with RNA sequencing.
- The biological model involves glioma tissue from mouse models.
- Key steps include tissue perfusion with Tyrode solution and cryoprotection.
- Sample preparation involves careful freezing and sectioning of the tissue.
- Laser capture microdissection software is employed for precise isolation of tumor areas.
Main Results
- The optimized method successfully preserves tissue morphology and RNA integrity.
- Microdissection allows for the analysis of differential mRNA expression across tumor areas.
- Insights into the molecular profiles of tumor regions can inform therapeutic strategies.
- The study underscores the potential of LMD in studying tumor progression.
Conclusions
- This study demonstrates an effective method for isolating tumor regions for molecular analysis.
- The protocol can enhance understanding of glioma heterogeneity and progression.
- Findings could lead to new approaches in developing targeted therapies for gliomas.
Frequently Asked Questions
What are the advantages of laser microdissection?
Laser microdissection provides high precision in isolating specific tissue areas, preserving both morphology and RNA quality for analysis.
How is the glioma tissue prepared for dissection?
Tissue is perfused with a Tyrode solution, followed by cryoprotection using sucrose before being frozen for slicing.
What types of outcomes can be obtained from this method?
The method allows analysis of differential mRNA expression and insights into molecular profiles pertinent to tumor heterogeneity.
Can this method be adapted for other types of tumors?
Yes, the protocol can potentially be applied to various tumor models to study their molecular characteristics and pathways.
What are the limitations of this study?
One limitation may be the reliance on specific tissue preparations, which could affect RNA yield and quality across different samples.
Executive Industry Relevance
Laser capture microdissection (LMD) enables spatially resolved molecular profiling of heterogeneous tumor subregions, supporting target validation in glioma research. By preserving tissue morphology and RNA integrity, the method facilitates mechanistic de-risking of invasion-associated pathways. This approach enhances predictive confidence in preclinical models by linking histological features such as oncostreams to differential gene expression.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by isolating mesenchymal cell accumulations (oncostreams) linked to tumor malignancy.
- Operational Value: Provides reproducible tissue sampling for RNA sequencing, reducing variability in target discovery workflows.
- Predictive Value: Supports biological de-risking by correlating histological invasion patterns with molecular signaling pathways.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream transcriptomic assays by maintaining high-quality RNA integrity.
- Operational Value: Ensures assay standardization through optimized perfusion, staining, and sectioning protocols.
- Scalability: Enables platform reuse across tumor models for consistent compound evaluation readiness.
Translational & Preclinical Research
- Scientific Value: Connects discovery-phase molecular profiling to preclinical continuity by analyzing differential mRNA expression in tumor invasion areas.
- Operational Value: Supports risk-adjusted advancement decisions through spatially resolved molecular readouts.
- Translational Biomarker Alignment: Facilitates identification of pathway-specific targets relevant to glioma heterogeneity and invasion.
Pipeline & Workflow Integration
LMD integrates into the discovery continuum from target identification through preclinical validation by enabling spatially resolved molecular analysis of tumor subregions.
- Discovery Biology: Supports hypothesis testing and pathway clarification by isolating discrete anatomical areas such as oncostreams and invasion fronts.
- Screening: Delivers assay readiness and quantitative mRNA outputs through preserved RNA integrity and reproducible sample preparation.
- Analytics: Generates differential mRNA expression measurements that enable comparison of signaling pathways across tumor subregions.
- Translational Research: Connects molecular profiling to preclinical continuity by linking histological features to therapeutic target identification.
- Enterprise Reuse: Functions as a reusable capability for studying tumor morphology and heterogeneity in diverse solid tumor models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity in tumor invasion pathways.
- Operational Value: Standardization, reproducibility, and scalability of tissue sampling for omics applications.
- Strategic Value: Improved go/no-go decisions, capital efficiency, and reduced late-stage biological risk in glioma drug development.
- Portfolio Impact: Risk-adjusted prioritization and advancement of targets based on spatially resolved molecular evidence.
Implementation Considerations
- Requires expertise in histology, cryosectioning, and laser microdissection instrumentation.
- Dependent on perfusion, freezing, and staining infrastructure to maintain tissue morphology and RNA integrity.
- Necessitates cross-team standardization of perfusion protocols (e.g., Tyrode solution and 30% sucrose) across pathology and molecular biology units.
- Adaptation considerations include model-specific optimization of section thickness and staining intensity for diverse tumor types.
- Practical limitations include dependency on RNA quality preservation, which may be compromised by suboptimal perfusion or mounting conditions.
Biopharma FAQs
Why does perfusion with Tyrode solution and 30% sucrose matter for LMD?
Perfusion with Tyrode solution followed by 30% sucrose preserves tissue morphology and RNA integrity, which is critical for obtaining high-quality laser microdissection samples suitable for downstream RNA sequencing. This approach prevents RNA degradation while maintaining cellular structure for accurate region-of-interest selection.
How does staining with Cresyl violet and eosin support LMD workflows?
Staining tumor sections with 4% Cresyl violet and 0.5% eosin provides clear nuclear and cellular visualization while preserving RNA integrity, enabling precise identification of heterogeneous subregions such as oncostreams and invasion areas. This staining method avoids the RNA damage associated with formaldehyde fixation while maintaining sufficient contrast for microdissection.
What quantitative measurements does LCD-enabled RNA sequencing enable?
Laser capture microdissection combined with RNA sequencing enables differential mRNA expression analysis between tumor subregions, such as mesenchymal-rich areas and invasive fronts. These quantitative measurements support pathway-level comparisons and target prioritization based on molecular signatures linked to malignancy.
Why are replication requirements important for LMD in target validation?
Replication requirements ensure reproducibility of tissue sampling and molecular profiling across samples, which is essential for cross-functional collaboration between histology, molecular biology, and pharmacology teams. Consistent LMD output reduces variability in target validation data and strengthens confidence in preclinical findings.
What statistical analysis capabilities are needed before implementing LMD in discovery pipelines?
Implementation requires statistical frameworks capable of comparing differential gene expression between microdissected tumor regions, including tools for identifying significantly altered pathways and controlling for multiple comparisons. These capabilities enable data-driven target selection and mechanistic de-risking based on LMD-derived transcriptomic profiles.
Chapters in this video
0:05
Introduction
1:17
Animal Perfusion and Brain Preservation
2:01
Glioma Brain Tumors Tissue Cryopreservation
2:52
Frozen Brain Tumor Tissue Sectioning
3:58
Cryopreserved Brain Tissue Section Fixation and Staining
4:48
Laser Capture Microdissection
6:30
Results: Representative RNA Quality Control and Library Preparation
7:55
Conclusion
